Manitoba – Winnipeg – Winnipeg
Corporation
www.cangene.com
Manitoba
Winnipeg
Winnipeg
Corporation
active
Cangene Corporation is an export driven Canadian company
focusing on the development, manufacture, and marketing of blood-
based and biotechnology-derived pharmaceutical products.
Publicly-traded on the Toronto Stock Exchange (TSX:CNJ), Cangene
has facilities in Winnipeg, Toronto, California, Maryland and
Florida, as well as a network of partners that span the globe.
In less than ten years, Cangene has achieved dramatic sales
growth in export markets, with export sales increasing from
CD$2.1 million in 1994 to more than CD$46 million in 2001.
This success has been driven by Cangene's international sales
strategy which is to develop a stable base of long-term
customers through a commitment to personal service and the
delivery of superior products. In the last five years, Cangene
has established partnerships with many types of organizations
including commercial distributors, governmental
organizations and national Ministries of Health, and has
successfully undertaken product registration in a number of
countries including Ireland, the United States, Poland,
Australia and the United Kingdom.
Early in fiscal 1998, Cangene began marketing its manufacturing
capability. Cangene has ample capacity to make its expertise
available to others due to its recent expansion of the
FDA-licensed Winnipeg manufacturing facility, a new 71,000 sq.
ft. Biotech Facility as well as its acquisition of Chesapeake
Biological Laboratories Inc., a 70A licensed manufacturing
facility in Baltimore, Maryland.
Cangene operates under cGMP (current good manufacturing
practices) and is licensed by the U.S. Food and Drug
Administration, the Canadian Health Protection Branch, and the
U.K. Medicines and Control Agency.
As part of continuous improvement efforts, in 1998 Cangene
undertook and was awarded the ISO 9001 designation. The
ISO 9001 designation is considered a key tool for managing
Cangene's quality systems and assisting in Cangene's future
export growth.
Country of Ownership: Canada
Year Established: 1984
Exporting: Yes
Quality Certification: ISO 9001
Primary Industry (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Primary Business Activity: Manufacturer / Processor / Producer
Total Sales ($CDN): $50,000,000 +
Export Sales ($CDN): $25,000,000 to $49,999,999
Number of Employees: 600
Services:
Contract manufacturing, Biopharmaceuticals, Biodefense, Hyperimmunes
Products:
Winrho sdfâ„¢ [rho(d) immune globulin], Varicella zoster immune globulin varizig, Hepagambâ„¢ (hpatitis b immune globulin), Accretropin (hgh), Leucotropinâ„¢ (gm-csf), Winrho®sdf (rho(d) immune globulin), Vaccinia immune globulin (vig), Anthrax immune globulin, Botulism antitoxin
Technology:
HYPERIMMUNES: Selected antibodies that have been highly
purified from specialty human plasma for therapeutic use.
Cangene specializes in high-quality, small batch production.
BIOPHARMACEUTICAL: Recombinant protein products purified from
host cell production systems for therapeutic use. Cangene uses a
strategy similar to that of the generic drug industry and
focuses on developing its own version of established products
using its own host systems.
INNOVATIVE PRODUCTS: Cangene develops innovative technologies
or products, through collaborations and in-house research, that
may become the platforms for its next generation of products.
No associations
LandOfFree
Cangene Corporation does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with Cangene Corporation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cangene Corporation will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-52108